Blood pressure homeostasis is maintained by a p311-tgf-β axis

Journal of Clinical Investigation

Volumn 123, Issue 10, 2013, Pages 4502-4512

  Badri, Kameswara Rao ^a,f   Yue, Ming ^a   Carretero, Oscar A ^b   Aramgam, Sree Latha ^a   Cao, Jun ^a   Sharkady, Stephen ^c   Kim, Gene H ^a   Taylor, Gregory A ^d   Byron, Kenneth L ^e   Schuger, Lucia ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f SAVANNAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; MESSENGER RNA; NERVE PROTEIN; P311 PROTEIN, MOUSE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL TONE; CONTROLLED STUDY; DEPOLARIZATION; DIASTOLIC BLOOD PRESSURE; HOMEOSTASIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ANIMAL; AORTOGRAPHY; C57BL MOUSE; CELL CULTURE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPOTENSION; KNOCKOUT MOUSE; MALE; METABOLISM; MUSCLE CONTRACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; AORTOGRAPHY; BLOOD PRESSURE; CELLS, CULTURED; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; HYPOTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NERVE TISSUE PROTEINS; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84885038963     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69884     Document Type: Article

References (45)

1. Pan D, Zhe X, Jakkaraju S, Taylor GA, Schuger L. P311 induces a TGF-β1-independent, nonfibrogenic myofibroblast phenotype. J Clin Invest. 2002;110(9):1349-1358.
2. Mariani L, et al. Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res. 2001;61(10):4190-4196.
3. Fujitani M, et al. P311 accelerates nerve regeneration of the axotomized facial nerve. J Neurochem. 2004;91(3):737-744.
4. Zhao L, et al. Identification of P311 as a potential gene regulating alveolar generation. Am J Respir Cell Mol Biol. 2006;35(1):48-54.
5. Tan J, et al. Investigating the role of P311 in the hypertrophic scar. PLoS One. 2010;5(4):e9995.
6. Paliwal S, Shi J, Dhru U, Zhou Y, Schuger L. P311 binds to the latency associated protein and downregulates the expression of TGF-β1 and TGF-β2. Biochem Biophys Res Commun. 2004;315(4):1104-1109.
7. Varshavsky A. The ubiquitin system. Trends Biochem Sci. 1997;22(10):383-387.
8. Stoven S, et al. Caspase-mediated processing of the Drosophila NF-kappaB factor Relish. Proc Natl Acad Sci U S A. 2003;100(10):5991-5996.
9. Alvarez M, Altafaj X, Aranda S, de la Luna S. DYR-K1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding. Mol Biol Cell. 2007;18(4):1167-1178.
10. Antonsson A, Payne E, Hengst K, McMillan NA. The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res. 2006;26(7):455-461.
11. Bies J, Markus J, Wolff L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem. 2002;277(11):8999-9009.
12. Fisher RC, et al. Normal myeloid development requires both the glutamine-rich transactivation domain and the PEST region of transcription factor PU. 1 but not the potent acidic transactivation domain. Mol Cell Biol. 1998;18(7):4347-4357.
13. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D. A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat Struct Biol. 2001;8(11):998-1004.
14. Huang W, Horvath E, Eklund EA. PU. 1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. J Biol Chem. 2007;282(9):6629-6643.
15. Taylor GA, et al. Behavioral characterization of P311 knockout mice. Genes Brain Behav. 2008;7(7):786-795.
16. Sun YG, et al. Involvement of P311 in the affective, but not in the sensory component of pain. Mol Pain. 2008;4:23.
17. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol. 2000;1(3):169-178.
18. Kitisin K, et al. Tgf-β signaling in development. Sci STKE. 2007;2007(399):cm1.
19. Massagué J. TGF-β in cancer. Cell. 2008;134(2):215-230.
20. Massagué J, Chen YG. Controlling TGF-β signaling. Genes Dev. 2000;14(6):627-644.
21. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF-β activation. J Cell Sci. 2003;116(pt 2):217-224.
22. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-β family signaling. Nature. 2003;425(6958):577-584.
23. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19(23):2783-2810.
24. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev. 2006;17(1-2):29-40.
25. Dennler S, et al. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17(11):3091-3100.
26. Kusanagi K, Kawabata M, Mishima HK, Miyazono K. Alpha-helix 2 in the amino-terminal mad homology 1 domain is responsible for specific DNA binding of Smad3. J Biol Chem. 2001;276(30):28155-28163.
27. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol. 2010;7(11):637-647.
28. Hirano K. Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol Sci. 2007;104(2):109-115.
29. Ghosh J, et al. The role of transforming growth factor β1 in the vascular system. Cardiovasc Pathol. 2005;14(1):28-36.
30. Zacchigna L, et al. Emilin1 links TGF-β maturation to blood pressure homeostasis. Cell. 2006;124(5):929-942.
31. August P, Suthanthiran M. Transforming growth factor β signaling, vascular remodeling, and hypertension. N Engl J Med. 2006;354(25):2721-2723.
32. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-β 1 in NIDDM. Diabetes Care. 1996;19(10):1113-1117.
33. Porreca E, et al. Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 1997;30(1 pt 1):134-139.
34. Derhaschnig U. Increased levels of transforming growth factor-β 1 in essential hypertension. Am J Hypertens. 2002;15(3):207-211.
35. Daniel C. Blocking of angiotensin II is more than blocking of transforming growth factor-β. Kidney Int. 2008;74(5):551-553.
36. Zhu S, Liu Y, Wang L, Meng QH. Transforming growth factor-β1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008;23(9):2841-2846.
37. Xu Z, et al. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol. 2008;51(1):62-70.
38. Yurovsky VV, et al. Autocrine TGF-β1 mediates angiotensin II-induced proliferative response of cerebral vessels in vivo. Am J Hypertens. 2007;20(9):950-956.
39. Argano C, et al. Transforming growth factor β1 T29C gene polymorphism and hypertension: relationship with cardiovascular and renal damage. Blood Press. 2008;17(4):220-226.
40. Li B, et al. TGF-β1 DNA polymorphisms, protein levels, and blood pressure. Hypertension. 1999;33(1 Pt 2):271-275.
41. Niu W. Evaluation of transforming growth factor β-1 gene 869T/C polymorphism with hypertension: a meta-analysis. Int J Hypertens. 2011;2011:934265.
42. Eiser AR. Does over-expression of transforming growth factor-β account for the increased morbidity in African-Americans?: possible clinical study and therapeutic implications. Med Hypotheses. 2010;75(5):418-421.
43. Liu YH, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2005;289(6):2616-2623.
44. Shi J, Badri KR, Choudhury R, Schuger L. P311-induced myofibroblasts exhibit ameboid-like migration through RalA activation. Exp Cell Res. 2006;312(17):3432-3442.
45. Taylor GA, Hudson E, Resau JH, Vande Woude GF. Regulation of P311 expression by Met-hepatocyte growth factor/scatter factor and the ubiquitin/proteasome system. J Biol Chem. 2000;275(6):4215-4219.